Tuoxin Pharmaceutical Group Co.,Ltd. (SHE:301089)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2023	FY 2022	FY 2020	FY 2020	FY 2019	FY 2017	FY 2016
Period Ending	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Jan 1, 2020	Jan 1, 2019	Dec 31, 2017	Dec 31, 2016
Nucleotide Series	146.23M	206.10M	250.61M
Nucleotide Series Growth	-29.05%	-17.76%	11.83%
Nucleoside Series	463.76M	377.92M	99.57M
Nucleoside Series Growth	22.71%	279.54%	2.20%
Pyrimidine Series	48.03M	48.79M	80.17M
Pyrimidine Series Growth	-1.57%	-39.14%	-22.89%
Purine Series	146.03M	124.64M	46.90M
Purine Series Growth	17.16%	165.74%	-35.50%
Other	31.46M	27.27M	25.22M
Other Growth	15.36%	8.10%	-15.18%
Total	835.51M	784.72M	502.48M
Total Growth	6.47%	56.17%	-4.82%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2023	FY 2022	FY 2020	FY 2020	FY 2019	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Jan 1, 2020	Jan 1, 2019	Dec 31, 2017	Dec 31, 2016
China	288.51M	325.00M	751.94M	699.12M	343.72M
China Growth	-11.23%	-56.78%	7.56%	103.40%	-22.08%
Overseas	89.84M	96.69M	83.57M	85.60M	158.77M
Overseas Growth	-7.09%	15.71%	-2.38%	-46.08%	82.87%
Total	378.34M	421.69M	835.51M	784.72M	502.48M
Total Growth	-10.28%	-49.53%	6.47%	56.17%	-4.82%

Source: S&P Global Market Intelligence.